OAKLAND PARK, FL--(Marketwired - Aug 22, 2016) - BioStem Technologies, Inc. (
Henry Van Vurst, CEO of BioStem Technologies, commented, "As a surviving cancer patient myself, I know first-hand the uncomfortable feelings of nausea while undergoing chemotherapy. We are very excited to announce our acquisition of Granisol -- a drug that relieves a major pain point for patients during this time. We look forward to marketing it effectively and profitably, and helping cancer patients feel better while fighting a very difficult battle."
Granisol® Oral Solution is proven to be a highly effective anti-nauseant during initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, total body irradiation, and fractionated abdominal radiation. Granisol® contains granisetron hydrochloride, an antiemetic (anti-nauseant) agent. The recommended adult dosage is 2 mg once daily, or 1 mg twice daily. In the 2 mg once-daily regimen, 10 mL of Granisol Oral Solution (2 teaspoonsful, equivalent to 2 mg of granisetron) are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first teaspoonful (5 mL) of Granisol Oral Solution is given up to 1 hour before chemotherapy, and the second teaspoonful (5 mL) of Granisol Oral Solution, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given.
About BioStem Technologies, Inc. (
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information:
BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
Howard Gostfrand
info@amcapventures.com
305.918.7000